- The FDA has announced an "ultra-fast" review of three psychedelic drugs aimed at treating mental health conditions, including depression and PTSD.
- President Donald Trump signed an executive order last weekend to accelerate access and ease restrictions on psychedelics, which are currently illegal under federal law.
- The FDA awarded priority review vouchers for psilocybin, the active ingredient in magic mushrooms, for difficult-to-treat depression, and for methylone, related to MDMA, for post-traumatic stress disorder.
- These moves reflect growing support for mind-altering substances among Trump's supporters, including combat veterans and the "Make America Healthy Again" movement led by Health Secretary Robert F. Kennedy Jr.
- The FDA also authorized initial testing of a drug related to ibogaine for alcohol use disorder, with podcaster Joe Rogan reportedly influencing Trump's interest in the substance.
IN FULL
